A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
The A-One study is a prospective, randomized controlled trial evaluating the use of the One Drop \| Premium \'On Track\' in combination with Afrezza treatment on the glycemic control, treatment adherence, social-cognitive barriers to adherence, and treatment satisfaction of people with Type 2 diabetes (T2D) and a hemoglobin A1c (A1c) \> 7.0% already prescribed an injectable rapid-acting insulin.
Epistemonikos ID: 23eb08353efa5037f4588fdac4e7c3e7d590d3bd
First added on: Dec 20, 2022